Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc Ord (OP: AZNCF )

132.65 +4.69 (+3.67%)
Streaming Delayed Price Updated: 3:47 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >
Why Are AstraZeneca Shares Trading Higher Today
Adding AstraZeneca Plc's (NASDAQ: AZN) Lynparza to Johnson & Johnson's (NYSE: JNJ) Zytiga (abiraterone) extended the time to live without disease... 
Via Benzinga
AstraZeneca Records Bumper COVID-19 Vaccine Sales Of ~$4B In FY21
AstraZeneca Plc's (NASDAQ: AZN) total revenue jumped 63% Y/Y to $12.0 
Via Benzinga
AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences
AstraZeneca plc (NASDAQ: AZN) has granted  
Via Benzinga
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is... 
Via Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ... 
Via Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... 
Via Benzinga
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine... 
Via Benzinga
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable... 
Via Benzinga
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use
AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third... 
Via Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron... 
Via Benzinga
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins
AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines... 
Via Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small... 
Via Benzinga
Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron
A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab... 
Via Benzinga
AstraZeneca - Amgen's Tezspire Biologic Scores FDA Approval For Severe Asthma
The FDA has approved AstraZeneca plc (NASDAQ: AZN) / Amgen Inc's (NASDAQ: AMGN) Tezspire (tezepelumab-ekko) as add-on maintenance treatment of adult... 
Via Benzinga
Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
COVID-19 vaccines from China's state-owned Sinopharm and Johnson & Johnson (NYSE: JNJ) and Russia developed Sputnik were found to produce little or no... 
Via Benzinga
AstraZeneca's COVID-19 Antibody Effective Against Omicron Variant
New preclinical data released by AstraZeneca Plc (NASDAQ: AZN) shows that its long-acting antibody Evusheld (tixagevimab co-packaged with cilgavimab) works against... 
Via Benzinga
Sanofi, Glaxo's COVID-19 Vaccine Candidate Works As Booster, But Data Readout Pushed Back
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) expect data from late-stage trials of its COVID-19 booster dose in Q1 2022, instead of this year.... 
Via Benzinga
Samsung Biologics, AstraZeneca Expand Collaboration To Include COVID-19, Cancer Therapy
Samsung Biologics Co Ltd said it would continue its partnership with AstraZeneca Plc (NASDAQ: AZN) on manufacturing biopharmaceuticals. According to Samsung, the production... 
Via Benzinga
AstraZeneca's Dapagliflozin No Longer Authorized For Type 1 Diabetes In UK
On 25 October 2021, the marketing authorization holder for dapagliflozin withdrew the indication for type 1 diabetes across Europe and the U.K. The SGLT2 inhibitor... 
Via Benzinga
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an... 
Via Benzinga
AstraZeneca's COVID-19 Therapy Wins FDA Approval As First Antibody To Prevent Infection In Immunocompromised
The FDA authorized the use of AstraZeneca Plc's (NASDAQ: AZN)antibody cocktail to prevent COVID-19 infections in individuals with weak immune systems or a... 
Via Benzinga
Exposures COVID-19 Product Safety
Mix & Match Pfizer, AstraZeneca COVID-19 Vaccine With Moderna Shows Improved Immune Response
A British study evaluating mixing COVID-19 vaccines showed a better immune response in people after the first dose of AstraZeneca Plc (NASDAQ: AZN) or ... 
Via Benzinga
Exposures COVID-19
Ionis, AstraZeneca Ink Licensing Pact For Eplontersen In Protein Misfolding Disorder
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has entered into a strategic collaboration agreement with AstraZeneca Plc (NASDAQ: AZN) to develop and... 
Via Benzinga
Valneva's COVID-19 Shot Fails As Booster In Pfizer/BioNTech Vaccinated Population
Valneva SE (NASDAQ: VALN) has responded to data published from the U.K COV-Boost COVID-19 vaccine trial that investigated the reactogenicity and immunogenicity of... 
Via Benzinga
Exposures COVID-19
AstraZeneca Blocks SOBI's $8B Buyout, Advent Withdraws The Bid - Report
AstraZeneca Plc (NASDAQ: AZN) blocked an $8 billion takeover of Swedish Orphan Biovitrum AB (OTC: BIOVF) by withholding its 8% stake in SOBI from a buyout offer by... 
Via Benzinga
Possible New Links Identified With AstraZeneca COVID-19 Shot, Blood Clots
Scientists have identified a possible reason the AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine may cause blood clots after the use of the shot was limited to... 
Via Benzinga
Exposures COVID-19
AstraZeneca-Merck's Lynparza Under FDA Priority Review For Breast Cancer Setting
The FDA has granted priority review for AstraZeneca Plc's (NASDAQ: AZN) supplemental marketing application for Lynparza (olaparib) for breast cancer.... 
Via Benzinga
Exposures Product Safety
AstraZeneca's COVID-19 Vaccine Turns Profitable In Q3; Reaffirms FY21 Guidance
AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine made a small contribution to earnings in Q3. It expects the shot to move to "modest profitability" on new... 
Via Benzinga
Exposures COVID-19
AstraZeneca Plans To Set Up Separate Division For Vaccines & Antibody Therapies - Report
AstraZeneca plc (NASDAQ: AZN) is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.